What is AKSM?
AKSM operates as a specialized leader in the medical technology landscape, focusing primarily on Extracorporeal Shock Wave Lithotripsy (ESWL) for the effective treatment of kidney stones. Beyond its core lithotripsy services, the company distinguishes itself by integrating advanced Intensity-Modulated Radiation Therapy (IMRT) and Image-Guided Radiation Therapy (IGRT) directly into urology practices. This integration strategy is designed to empower physician-owned practices, allowing them to offer comprehensive, high-acuity care without the need for external referrals. By providing both the technical infrastructure and the clinical resources—such as white papers and patient education materials—AKSM serves as a critical partner for urology groups aiming to modernize their service offerings and improve patient outcomes through physician-led ownership models.
How much funding has AKSM raised?
AKSM has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in AKSM
PPP
Public-Private Partnership
What's next for AKSM?
With this major enterprise-level funding, AKSM is poised to scale its integrated care platform, likely focusing on the expansion of its IMRT/IGRT service lines across new clinical territories. The strategic deployment of this capital will likely prioritize the acquisition of advanced medical hardware and the strengthening of its physician partnership network. As the healthcare industry continues to shift toward value-based care and integrated service delivery, AKSM's model of physician ownership provides a robust framework for long-term growth. Future initiatives will likely involve deepening the technological integration within existing practices to ensure that urology providers remain at the forefront of minimally invasive stone management and radiation oncology, thereby securing a competitive advantage in an increasingly consolidated healthcare market.
See full AKSM company page
